US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Actuate Therapeutics Inc

8.78

-0.2600-2.88%

Volume:6.18K

Turnover:54.22K

Market Cap:171.49M

PE:-2.69

High:9.00

Open:9.00

Low:8.64

Close:9.04

Loading ...

Overview Company News Filings

ACTU: Aussies could be $165K worse off under a push to change superannuation guarantee

Sydney Morning Herald

Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU

MT Newswires Live

BRIEF-Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation For Elraglusib For The Treatment Of Pancreatic Cancer

Actuate Therapeutics announces EMA granted OMPD to elraglusib

Actuate Therapeutics Inc: to Report Topline Data From Phase 2 Trial of Elraglusib in 1H 2025

THOMSON REUTERS

Actuate Therapeutics Receives Ema Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

BRIEF-Actuate Therapeutics Announces Interim Phase 2 Data Of Elraglusib

Actuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal Cancer

Actuate Therapeutics Reports Phase 2 Trial Success for Elraglusib in Metastatic Pancreatic Cancer

MT Newswires Live

Actuate Therapeutics announces interim Phase 2 data of elraglusib

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Inc - Statistical Significance Met on Primary Endpoints in Phase 2 Trial

THOMSON REUTERS

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Therapeutics Inc - Elraglusib in Combination With Gnp Shows Favorable Risk-Benefit Profile

THOMSON REUTERS

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

RBA resists call for Christmas rate cut, keeps things on-hold despite GDP slump

The Market Herald

The staggering number of Aussies set to lose their jobs to AIWithout immediate action, Australian workers are highly vulnerable to mass job losses.2 min read

Actuate Therapeutics to Join Russell 2000 Index; Shares Up Pre-Bell

MT Newswires Live

Actuate Therapeutics added to Russell 2000 Index

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACTU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":8.78,"timestamp":1745595690297,"preClose":9.04,"halted":0,"volume":6178,"delay":0,"floatShares":5961432,"shares":19531636,"eps":-3.258828,"marketStatus":"Trading","change":-0.26,"latestTime":"04-25 11:42:05 EDT","open":9,"high":9,"low":8.64,"amount":54221.983072,"amplitude":0.039823,"askPrice":8.8,"askSize":100,"bidPrice":8.63,"bidSize":49,"shortable":3,"etf":0,"ttmEps":-3.258828,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745611200000},"marketStatusCode":2,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":9.04,"preHourTrading":{"tag":"盘前","latestPrice":9.03,"preClose":9.04,"latestTime":"08:07 EDT","volume":226,"amount":2000.099774,"timestamp":1745582826035},"postHourTrading":{"tag":"盘后","latestPrice":9.04,"preClose":9.04,"latestTime":"16:00 EDT","volume":48,"amount":433.91999999999996,"timestamp":1745524801479},"volumeRatio":0.15995},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":5961432,"roa":"-255.41%","roe":"--","lyrEps":-3.258828,"volumeRatio":0.15995,"shares":19531636,"dividePrice":0,"high":9,"amplitude":0.039823,"preClose":9.04,"low":8.64,"week52Low":5.51,"pbRate":"1645.98","week52High":11.73,"institutionHeld":0,"latestPrice":8.78,"committee":-0.342282,"eps":-3.258828,"divideRate":0,"volume":6178,"delay":0,"ttmEps":-3.258828,"open":9,"prevYearClose":7.96,"prevWeekClose":8,"prevMonthClose":6.77,"prevQuarterClose":6.77,"fiveDayClose":8,"twentyDayClose":7.58,"sixtyDayClose":8.79},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2504824901","title":"ACTU: Aussies could be $165K worse off under a push to change superannuation guarantee","url":"https://stock-news.laohu8.com/highlight/detail?id=2504824901","media":"Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504824901?lang=en_us&edition=fundamental","pubTime":"2025-01-17 12:29","pubTimestamp":1737088187,"startTime":"0","endTime":"0","summary":"Aussies could be $165,000 worse-off in retirement if a proposed change to superannuation guarantee is given the go ahead, the peak union body warns.","market":"us","thumbnail":"https://images.perthnow.com.au/publication/C-17419061/aaf4995610415e620b55b7c8a88e1c3d51bbe17e.jpg","type":0,"news_type":0,"thumbnails":["https://images.perthnow.com.au/publication/C-17419061/aaf4995610415e620b55b7c8a88e1c3d51bbe17e.jpg"],"rights":{"source":"perthnow_stock","url":"https://www.perthnow.com.au/business/actu-aussies-could-be-165k-worse-off-under-a-push-to-change-superannuation-guarantee-c-17419061","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.perthnow.com.au/business/actu-aussies-could-be-165k-worse-off-under-a-push-to-change-superannuation-guarantee-c-17419061","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"perthnow_stock","symbols":["XKO.AU","XAO.AU","XJO.AU","BK4139","ACTU"],"gpt_icon":0},{"id":"2501850577","title":"Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2501850577","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501850577?lang=en_us&edition=fundamental","pubTime":"2025-01-07 23:34","pubTimestamp":1736264082,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics  said Tuesday that the European Medicines Agency has granted orphan medicinal product designation to elraglusib for the treatment of pancreatic ductal adenocarcinoma.The company said the designation is granted to therapies intended for the treatment of life-threatening diseases \"that affect no more than two in 10,000 people in the European Union and for which no satisfactory therapy is available.\"The label also provides certain benefits like reduced regulatory fees, and a potential 10-year market exclusivity, the firm said. It also has an orphan drug designation for Elraglusib in the US for the same indication.\"We look forward to reporting topline data from our Phase 2 trial in 1H 2025 and working closely with the EMA and the FDA to accelerate elraglusib's clinical development program in metastatic pancreatic cancer,\" said Chief Executive Officer Daniel Schmitt.Price: 7.85, Change: -0.43, Percent Change: -5.19","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","ACTU","BK4156","BK4139"],"gpt_icon":0},{"id":"2501910206","title":"BRIEF-Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation For Elraglusib For The Treatment Of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501910206","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501910206?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:11","pubTimestamp":1736255505,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation For Elraglusib For The Treatment Of Pancreatic CancerJan 7 (Reuters) - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA3HLZYK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2501209815","title":"Actuate Therapeutics announces EMA granted OMPD to elraglusib","url":"https://stock-news.laohu8.com/highlight/detail?id=2501209815","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501209815?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:11","pubTimestamp":1736255488,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to elraglusi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-ema-granted-ompd-to-elraglusib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-ema-granted-ompd-to-elraglusib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ACTU","BK4139"],"gpt_icon":0},{"id":"2501205703","title":"Actuate Therapeutics Inc: to Report Topline Data From Phase 2 Trial of Elraglusib in 1H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501205703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501205703?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA3HLZYK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2501057802","title":"Actuate Therapeutics Receives Ema Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501057802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501057802?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA3HLZYK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2501068022","title":"Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501068022","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501068022?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254800,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, Jan.  07, 2025  (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on develop","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005368/0/en/Actuate-Therapeutics-Receives-EMA-Orphan-Medicinal-Product-Designation-for-Elraglusib-for-the-Treatment-of-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ACTU","BK4139","BK4156"],"gpt_icon":0},{"id":"2492950256","title":"BRIEF-Actuate Therapeutics Announces Interim Phase 2 Data Of Elraglusib","url":"https://stock-news.laohu8.com/highlight/detail?id=2492950256","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492950256?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:05","pubTimestamp":1734444317,"startTime":"0","endTime":"0","summary":"Dec 17  - Actuate Therapeutics Inc   :   * ACTUATE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 2 DATA OF ELRAGLUSIB IN FIRST LINE TREATMENT OF METASTATIC PANCREATIC CANCER   * ACTUATE THERAPEUTICS INC - ELRAGLUSIB IN COMBINATION WITH GNP SHOWS FAVORABLE RISK-BENEFIT PROFILE   * ACTUATE THERAPEUTICS INC - TRIAL MET PRIMARY SAFETY ENDPOINT, FAVORABLE RISK-BENEFIT PROFILESource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139","LENZ"],"gpt_icon":0},{"id":"2492957754","title":"Actuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492957754","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492957754?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:52","pubTimestamp":1734443520,"startTime":"0","endTime":"0","summary":"Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal cancer.The stock was up 12% to $9.73 in pre-market trading.The clinical-stage biopharmaceutical company said that the trial has shown that the combination of the treatments statistically increases in one-year the survival rate and median overall survival when compared to taking gemcitabine/nab-paclitaxel alone.Pancreatic ductal adenocarcinoma is the common type of this lethal disease, with an average five-year survival rate of less than 10%, according to the National Institutes of Health.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU","LENZ"],"gpt_icon":0},{"id":"2492439957","title":"Actuate Therapeutics Reports Phase 2 Trial Success for Elraglusib in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492439957","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492439957?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:46","pubTimestamp":1734443195,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics  said Tuesday that its phase 2 trial of elraglusib with gemcitabine/nab-paclitaxel, or GnP, in metastatic pancreatic cancer met primary endpoints of one-year survival rate.The study demonstrated a one-year survival rate of 43.6% in the elraglusib-GnP arm compared to 22.5% in the GnP control arm. Median overall survival was 9.3 months for the elraglusib combination versus 7.2 months for GnP alone, Actuate said.Actuate said it plans to share topline data and discuss next steps, including a phase 3 registration trial, with the US Food and Drug Administration in H1 2025.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACTU","BK4139","LENZ"],"gpt_icon":0},{"id":"2492595789","title":"Actuate Therapeutics announces interim Phase 2 data of elraglusib","url":"https://stock-news.laohu8.com/highlight/detail?id=2492595789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492595789?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:35","pubTimestamp":1734442550,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-interim-phase-2-data-of-elraglusib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-interim-phase-2-data-of-elraglusib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ACTU"],"gpt_icon":0},{"id":"2492521399","title":"Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492521399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492521399?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:28","pubTimestamp":1734442097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA6WXZTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2492295213","title":"Actuate Therapeutics Inc - Statistical Significance Met on Primary Endpoints in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492295213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492295213?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:28","pubTimestamp":1734442097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA6WXZTM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2492954802","title":"Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954802?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:00","pubTimestamp":1734440400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUAVT686:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2492954385","title":"Actuate Therapeutics Inc - Elraglusib in Combination With Gnp Shows Favorable Risk-Benefit Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954385","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954385?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:00","pubTimestamp":1734440400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUAVT686:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2492954671","title":"Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954671","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954671?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:00","pubTimestamp":1734440400,"startTime":"0","endTime":"0","summary":"Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate and 37% Reduction in Risk of Death Two Month (29%) Increase in Med","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998209/0/en/Actuate-Therapeutics-Announces-Positive-Interim-Phase-2-Data-of-Elraglusib-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PR","LENZ","BK4213","BK4139","ACTU"],"gpt_icon":0},{"id":"2490055551","title":"RBA resists call for Christmas rate cut, keeps things on-hold despite GDP slump","url":"https://stock-news.laohu8.com/highlight/detail?id=2490055551","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490055551?lang=en_us&edition=fundamental","pubTime":"2024-12-10 11:30","pubTimestamp":1733801400,"startTime":"0","endTime":"0","summary":"The Reserve Bank of Australia has left the cash rate on hold in a widely anticipated move which nevertheless means many Australian homeowners will head into Christmas with little mortgage relief amid a continuing cost-of-living crisis, in addition to recent data which has shown the national economy in a slump.At its final meeting for the year, the RBA announced the cash rate would stay at 4.35% – a position it has been at since as far back as November 2023 when it was pushed up from a previous setting of 4.10%.The RBA’s decision to keep the rate steady over nine consecutive meetings had seen it deviate from the actions of many other central banks, which have eased rates in the face of a global prevalence of higher prices.The following day, the ABS reported household spending had grown 0.8% in October – seasonally adjusted – with spending in all nine categories; the overall number showed a recovery from a 0.2% drop in September","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/rba-resists-call-for-christmas-rate-cut-keeps-things-on-hold-despite-gdp-slump-2024-12-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["XAO.AU","XJO.AU","XKO.AU","ACTU","BK4139"],"gpt_icon":0},{"id":"2490706448","title":"The staggering number of Aussies set to lose their jobs to AIWithout immediate action, Australian workers are highly vulnerable to mass job losses.2 min read","url":"https://stock-news.laohu8.com/highlight/detail?id=2490706448","media":"7NEWS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490706448?lang=en_us&edition=fundamental","pubTime":"2024-12-10 00:00","pubTimestamp":1733760000,"startTime":"0","endTime":"0","summary":"One in three Australians are at risk of losing their job to AI by 2030, the Australian Council Of Trade Unions (ACTU) revealed.It wants workers rights embedded in AI legislation, so that the future of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"7news_stock","url":"https://7news.com.au/news/unions-call-for-worker-centric-ai-laws-as-report-finds-one-in-three-aussies-at-risk-of-losing-their-job-to-the-technology-by-2030-c-17039021","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://7news.com.au/news/unions-call-for-worker-centric-ai-laws-as-report-finds-one-in-three-aussies-at-risk-of-losing-their-job-to-the-technology-by-2030-c-17039021","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"7news_stock","symbols":["XJO.AU","BK4139","XAO.AU","ACTU","XKO.AU"],"gpt_icon":0},{"id":"2486006741","title":"Actuate Therapeutics to Join Russell 2000 Index; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2486006741","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486006741?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:25","pubTimestamp":1732631119,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics  said Tuesday it will join the Russell 2000 Index effective after the opening of markets on Dec. 23.The company said it will be added to the index as part of the planned Q4 initial public offering additions.Shares of Actuate Therapeutics rose 9.3% in premarket activity Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","ACTU"],"gpt_icon":0},{"id":"2486070141","title":"Actuate Therapeutics added to Russell 2000 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2486070141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486070141?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:16","pubTimestamp":1732626972,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced that the Company will be added to the Russell 2000 Index as part of the planned fourth quarter IPO additions ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-added-to-russell-2000-index?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-added-to-russell-2000-index?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACTU","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1745380800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2025-04-24","current":-6.442463,"percent":0.034682,"low":-7.551405,"twenty":-5.997615,"median":-5.540019,"eighty":-4.994326,"high":-3.846419,"avg":-5.526003,"sd":0.565283,"marketCap":175784724},"quantilePoints":[{"date":"2024-08-16","current":-6.123063,"twenty":-6.192654,"median":-6.024237,"eighty":-5.763747,"marketCap":170040047},{"date":"2024-08-23","current":-5.540019,"twenty":-6.078798,"median":-5.925411,"eighty":-5.709316,"marketCap":153848669},{"date":"2024-08-30","current":-5.595075,"twenty":-6.012125,"median":-5.708628,"eighty":-5.532512,"marketCap":155377600},{"date":"2024-09-06","current":-5.608839,"twenty":-5.962574,"median":-5.601957,"eighty":-5.528759,"marketCap":155759833},{"date":"2024-09-13","current":-5.471267,"twenty":-5.922658,"median":-5.608839,"eighty":-5.528759,"marketCap":151939417},{"date":"2024-09-20","current":-5.636367,"twenty":-5.87999,"median":-5.601957,"eighty":-5.515244,"marketCap":156524298},{"date":"2024-09-27","current":-4.113941,"twenty":-5.797406,"median":-5.560665,"eighty":-5.483587,"marketCap":118557030},{"date":"2024-10-04","current":-4.749671,"twenty":-5.732715,"median":-5.540019,"eighty":-4.899514,"marketCap":136877705},{"date":"2024-10-11","current":-4.852689,"twenty":-5.672153,"median":-5.519373,"eighty":-4.774612,"marketCap":139846513},{"date":"2024-10-18","current":-5.042459,"twenty":-5.644693,"median":-5.512491,"eighty":-4.820157,"marketCap":145315371},{"date":"2024-10-25","current":-5.754096,"twenty":-5.644693,"median":-5.505609,"eighty":-4.820157,"marketCap":165823589},{"date":"2024-10-31","current":-5.801538,"twenty":-5.759014,"median":-5.512491,"eighty":-4.836423,"marketCap":167190804},{"date":"2024-11-08","current":-5.930311,"twenty":-5.818052,"median":-5.520312,"eighty":-4.866244,"marketCap":170901815},{"date":"2024-11-15","current":-5.869501,"twenty":-5.914108,"median":-5.540019,"eighty":-4.932663,"marketCap":166995487},{"date":"2024-11-22","current":-6.178422,"twenty":-5.935733,"median":-5.560665,"eighty":-4.991319,"marketCap":175784724},{"date":"2024-11-29","current":-5.581175,"twenty":-5.958745,"median":-5.588125,"eighty":-5.03075,"marketCap":158792200},{"date":"2024-12-06","current":-6.013664,"twenty":-5.987349,"median":-5.608839,"eighty":-5.042459,"marketCap":171097131},{"date":"2024-12-13","current":-5.691014,"twenty":-5.987349,"median":-5.622603,"eighty":-5.049236,"marketCap":161917262},{"date":"2024-12-20","current":-4.839764,"twenty":-5.96561,"median":-5.608839,"eighty":-5.042459,"marketCap":137698033},{"date":"2024-12-27","current":-5.766528,"twenty":-5.96448,"median":-5.608839,"eighty":-5.040117,"marketCap":164065742},{"date":"2025-01-03","current":-5.464471,"twenty":-5.964763,"median":-5.595075,"eighty":-5.046525,"marketCap":155471822},{"date":"2025-01-10","current":-5.491931,"twenty":-5.962017,"median":-5.595075,"eighty":-5.051947,"marketCap":156253088},{"date":"2025-01-17","current":-5.869501,"twenty":-5.952793,"median":-5.601957,"eighty":-5.10132,"marketCap":166995487},{"date":"2025-01-24","current":-7.551405,"twenty":-5.965328,"median":-5.622603,"eighty":-5.16928,"marketCap":214847996},{"date":"2025-01-31","current":-6.061719,"twenty":-6.031513,"median":-5.643249,"eighty":-5.172381,"marketCap":172464345},{"date":"2025-02-07","current":-6.05554,"twenty":-6.061192,"median":-5.677284,"eighty":-5.192919,"marketCap":172288561},{"date":"2025-02-14","current":-5.306578,"twenty":-6.058374,"median":-5.670419,"eighty":-5.230693,"marketCap":150979546},{"date":"2025-02-21","current":-5.375227,"twenty":-6.05554,"median":-5.643249,"eighty":-5.225451,"marketCap":152932709},{"date":"2025-02-28","current":-4.757385,"twenty":-6.049288,"median":-5.622603,"eighty":-5.16928,"marketCap":135354237},{"date":"2025-03-07","current":-4.76425,"twenty":-6.047989,"median":-5.595075,"eighty":-5.042459,"marketCap":135549553},{"date":"2025-03-14","current":-5.114361,"twenty":-6.034259,"median":-5.57431,"eighty":-5.03075,"marketCap":145510688},{"date":"2025-03-21","current":-5.003646,"twenty":-6.020529,"median":-5.560665,"eighty":-5.03075,"marketCap":136526135},{"date":"2025-03-28","current":-5.425986,"twenty":-6.013664,"median":-5.543435,"eighty":-5.03075,"marketCap":148049800},{"date":"2025-04-04","current":-5.168287,"twenty":-6.0068,"median":-5.540019,"eighty":-4.997657,"marketCap":141018411},{"date":"2025-04-11","current":-5.089546,"twenty":-5.987349,"median":-5.520321,"eighty":-4.981461,"marketCap":138869931},{"date":"2025-04-17","current":-5.891275,"twenty":-5.969958,"median":-5.530635,"eighty":-4.987756,"marketCap":160745364},{"date":"2025-04-24","current":-6.442463,"twenty":-5.997615,"median":-5.540019,"eighty":-4.994326,"marketCap":175784724}],"updateTime":1745595725885}}}